Introduction {#sec1}
============

Food intake and energy homeostasis are controlled by a dynamic interplay of gut-brain signaling pathways that are not well-defined but are thought to become dysregulated in obesity ([@ref94]). Recent studies in humans and rodents suggest a critical role for the endocannabinoid (eCB) system in these processes ([@ref30], [@ref31]; [@ref26]). The eCB system is located in cells throughout the body and is comprised of the eCBs, 2-arachidonoyl-*sn*-glycerol (2-AG) and anandamide (AEA), their biosynthetic and degradative enzymes, and the cannabinoid receptor subtypes 1 and 2 \[CB~1~R and CB~2~R, respectively ([@ref77]; [@ref75])\]. CB~1~Rs in the brain control food intake and energy homeostasis ([@ref30]; [@ref91]); however, targeting central CB~1~Rs with antagonists for the treatment of human obesity led to psychiatric side-effects that preclude their use as safe and effective anti-obesity therapeutics ([@ref14]). In contrast, CB~1~Rs antagonists that are restricted to the periphery and do not readily cross the blood-brain barrier are associated with improvements in a variety of metabolic parameters in rodents, and may be an effective anti-obesity strategy that is devoid of psychiatric side-effects inherent to brain-permeable drugs ([@ref61]; [@ref78]; [@ref16]; [@ref27], [@ref29], [@ref28]; [@ref97], [@ref98]; [@ref62]). Nonetheless, peripheral mechanisms influence brain function \[e.g., signals from the gut microbiome ([@ref11])\]; thus, the impact of disrupting endocannabinoid signaling at peripheral CB~1~Rs on these functions is largely unknown and warrants future investigation.

Studies from our lab and others suggest key roles for the peripheral eCB system in controlling feeding behavior and energy homeostasis ([@ref26]; [@ref41]; [@ref91]). Indeed, eCB levels are increased in the small intestinal epithelium of rodents (1) during a fast ([@ref38]; [@ref48]; [@ref28]; [@ref2]), (2) after oral exposure to dietary fats ([@ref27], [@ref29]), and (3) in a mouse model of western diet-induced obesity (DIO) ([@ref2]). Pharmacological inhibition of elevated eCB signaling at small-intestinal CB~1~Rs with peripherally-restricted CB~1~R antagonists blocks (1) re-feeding after a fast ([@ref28]), (2) intake of dietary fats based on their orosensory properties ([@ref27], [@ref29]), and (3) overeating (i.e., increased meal size and caloric intake) associated with DIO, ([@ref2]). These studies suggest that the eCB system in the small intestinal epithelium plays a key role in feeding behavior and energy balance, and becomes dysregulated in DIO.

The mechanism(s) underlying eCB control of gut-brain signaling and its dysregulation in DIO is largely unknown. Nonetheless, CB~1~Rs are expressed on the afferent vagus nerve and suggested to control feeding behavior and energy balance by directly modifying gut-brain vagal signaling important for food intake ([@ref8], [@ref9]). For example, expression of CB~1~Rs in the rat nodose ganglion is upregulated after fasting, and refeeding or administration of the gut-derived satiation peptide, cholecystokinin (CCK), reversed this effect ([@ref8], [@ref10]). Moreover, both, fasting-induced increases in CB~1~R expression in the nodose ganglion and the ability for CCK to decrease this response were blunted in rats fed a high-fat diet ([@ref15]). Vianna and colleagues, however, reported that select deletion of CB~1~Rs on the afferent and efferent vagus nerve had no effect on food intake or body weight in mice fed a standard rodent chow or high-fat diet ([@ref104]). These findings suggest that CB~1~Rs expressed on the vagus nerve may be dispensable for feeding behavior and maintenance of body weight.

Dietary fats and other macronutrients are sensed by enteroendocrine cells in the small intestinal epithelium and stimulate release of satiation peptides including CCK ([@ref67], [@ref66]; [@ref81]; [@ref94]), which controls meal size and satiation by activating CCK~A~ receptors on the afferent vagus nerve ([@ref92], [@ref93]; [@ref88]; [@ref80]; [@ref32]; [@ref53]; [@ref87]) and possibly in the brain ([@ref83]; [@ref85]). Furthermore, CCK-containing I-cells in the upper small intestinal epithelium of mice express genes for CB~1~Rs ([@ref96]). Thus, CB~1~Rs in the small intestinal epithelium may control feeding behavior by an indirect mechanism that includes controlling release of gut-derived satiation peptides. We investigated this possibility by testing the hypothesis that elevated endocannabinoid activity at CB~1~Rs in the gut of mice rendered DIO by chronic access to a high-fat and sucrose diet inhibits nutrient-induced release of satiation peptides, which in turn, leads to overeating by delaying satiation.

Materials and Methods {#sec2}
=====================

Animals {#sec3}
-------

Eight-week old C57BL/6 mice (Taconic, Oxnard, CA, USA) were group-housed with *ad libitum* food and water access and maintained on a 12 h dark/light cycle. C57BL/6-Tg (Cck-EGFP)2Mirn/J mice with enhanced green fluorescent protein on the promoter for cholecystokinin were used for immunohistochemistry and fluorescence-activated cell sorting (FACS) of small intestinal CCK-containing cells (Jackson Laboratories, Bar Harbor, ME, USA). Test diets included Teklad 2020x soy-purified Standard Rodent Chow (SD; Envigo, Huntingdon, UK) or Western-style diet (WD; Research Diets D12709B, New Brunswick, NJ, USA; 40% kcal as fat, 43% kcal as carbohydrates, mainly sucrose). Body weights were recorded every other day at noon. To assess feeding behaviors, mice were single-housed in behavior chambers (TSE Systems, Chesterfield, MO, USA). All procedures met the U.S. National Institute of Health guidelines for care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee of the University of California, Riverside.

### Feeding Behaviors {#sec4}

Animals were placed into feeding chambers 5 days prior to recording for acclimation, and testing began at 60 days after being placed on their respective experimental diets. Feeding behaviors were assessed starting 1 h prior to dark cycle (1,700 h) over a 24 h period for acclimation and for 12 h following drug administrations. Behavioral parameters include total caloric intake, average meal size, average rate of intake, average number of meals, first meal size, average meal duration, and average post meal interval. Data were processed using TSE Phenomaster software.

Chemicals and Administration Schedule {#sec5}
-------------------------------------

AM6545, a peripherally-restricted CB~1~R neutral antagonist, was given by IP injection at 10 mg per kg (Northeastern University Center for Drug Discovery, Boston, MA, USA). Devazepide (Tocris, Bristol, UK), a CCK~A~ receptor antagonist, was given IP at 0.3 mg per kg. Both drugs were dissolved in vehicle consisting of 7.5% DMSO, 7.5% Tween80, and 85% sterile saline, and warmed in a water bath to ensure solubility. All control conditions were matched, using vehicle in place of drugs and injections occurred 1 h prior to behavior recording (1,600 h). A 72-h washout period was allowed between drug treatments. JZL184 (Tocris, Bristol, UK), a potent inhibitor of monoacylglycerol lipase (MGL), was used to prevent monoacylglycerol hydrolysis in the diacylglycerol lipase (DGL) assay and to validate our MGL assay (described below). Tetrahydrolipstatin (Tocris, Bristol, UK), a lipase inhibitor used routinely to study DGL activity ([@ref40]; [@ref51]), was used to validate our DGL assay.

Measurement of Intestinal Lipids {#sec6}
--------------------------------

### Tissue Harvest and Lipid Extraction {#sec7}

Animals were anesthetized with isoflurane at time of tissue harvest (1,500--1,700 h) following *ad libitum* food and water access. Blood was collected by cardiac puncture and deposited into vacutainers containing EDTA; plasma was collected as supernatant following 10 min centrifugation at 1,500 *g* (kept at 4°C). Jejunum was quickly removed and washed in phosphate-buffered saline (PBS), opened longitudinally on a stainless steel tray on ice, and contents were removed. Jejunum mucosa was isolated using glass slides to scrape the epithelial layer and was snap-frozen in liquid N~2~. Samples were stored at −80°C pending analysis. Frozen tissues were weighed and then homogenized in 1 ml methanol solution containing 500 pmol \[^2^H~5~\]-2-AG (Cayman Chemicals, Ann Arbor, MI) as an internal standard. Lipids were extracted as previously described ([@ref2]) and resuspended in 0.1 ml methanol:chloroform (9:1) and analyzed *via* ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).

### LCMS Detection of 2-Arachidonoyl-*sn*-Glycerol and Other Monoacylglycerols {#sec8}

Data were acquired using an Acquity I Class UPLC with direct connection to a Xevo TQ-S Micro Mass Spectrometer (Waters Corporation, Milford, MA, USA) with electrospray ionization (ESI) sample delivery. Lipids were separated using an Acquity UPLC BEH C~18~ column (2.1 mm × 50 mm i.d., 1.7 μm, Waters Corporation) and inline Acquity guard column (UPLC BEH C~18~ VanGuard PreColumn; 2.1 mm × 5 mm i.d.; 1.7 μm, Waters Corporation), and eluted by a gradient of water and methanol (containing 0.25% acetic acid, 5 mM ammonium acetate) at a flow rate of 0.4 ml per min and gradient: 80% methanol 0.5 min, 80 to 100% methanol 0.5--2.5 min, 100% methanol 2.5--4.5 min, 100 to 80% methanol 4.5--4.6 min, and 80% methanol 4.6--5.5 min. The column was maintained at 40°C, and samples were kept at 10°C in accompanying sample manager. MS/MS detection was in positive ion mode with capillary voltage maintained at 1.10 kV, and argon (99.998%) was used as collision gas. Cone voltages and collision energies for respective analytes: 2-AG (20:4) = 30v, 12v; 2-DG (22:6) = 34v, 14v; 2-PG (16:0) = 18v, 10v; 2-OG (18:1) = 42v, 10v; 2-LG (18:2) = 30v, 10v; monononadecadienoin (19:2 monoacylglycerol; product of DGL assay, see below in "[DGL Activity Assay](#sec16){ref-type="sec"}") = 18v, 10v; and \[^2^H~5~\]-2-AG = 25v, 44v. Lipids were quantified using a stable isotope dilution method detecting H^+^ or Na^+^ adducts of the molecular ions \[M + H/Na\]^+^ in multiple reaction monitoring (MRM) mode. Acyl migration occurs in monoacylglycerols; thus, the sum of 2-AG and 1-AG is presented. Tissue processing and LCMS analyses for experiments occurred independently of other experiments. Extracted ion chromatograms for MRM transitions were used to quantify analytes: 2-AG (*m/z* = 379.3 \> 287.3), 2-DG (*m/z* = 403.3 \> 311.1), 2-PG (*m/z* = 331.3 \> 239.3), 2-OG (*m/z* = 357.4 \> 265.2), 2-LG (*m/z* = 355.3 \> 263.3), 19:2 monoacylglycerol (*m/z* = 386.4 \> 277.2), and \[^2^H~5~\]-2-AG (*m/z* = 384.3 \> 93.4), which was used as an internal standard for quantitation of monoacylglycerols.

ELISA Analysis of CCK-8 Octapeptide {#sec9}
-----------------------------------

Mice were fasted for 12 h in order to ensure an empty stomach. Mice were pretreated with CB~1~R ligands, then administered corn oil (0.5 ml) by oral gavage 30 min later. Levels of CCK-8 were assessed in blood plasma 30 min following gavage. Blood was placed in BD vacutainer lavender-top EDTA blood collection tubes on ice and plasma obtained by centrifugation of tubes at 1,500 *g* for 10 min at 4°C by a sensitive and selective CCK-8 ELISA (Cloud Clone Corp; Katy, TX, USA). Mice were maintained for 60 days on standard diet (SD) and given IP injection of vehicle or the general cannabinoid receptor agonist, WIN55,212-2 (3 mg per kg), or WIN 55,212-2 in combination with the peripherally-restricted CB~1~R antagonist, AM6545 (10 mg per kg). In addition, mice maintained for 60 days on Western diet (WD) were given IP injection of vehicle or AM6545 (10 mg per kg). ELISA reaction was measured using iMark microplate reader (BioRad, Hercules, CA, USA).

Immunohistochemistry {#sec10}
--------------------

Intact proximal small intestine was removed, and contents were flushed with ice-cold 4% paraformaldehyde (PFA)/PBS, then fixed in 4% PFA for 4 h at 4°C. Samples were transferred to 20% sucrose/PBS and incubated for 1 day at 4°C for cryopreservation. Cross sections of upper small intestine were cut and frozen in OCT (Fisher Healthcare, Chino, CA, USA) on dry ice. About 16 μm sections were taken on a cryostat (Leica) and mounted onto charged glass slides. Sections were permeabilized with 0.5% Tween-20/PBS and then blocked with 0.1% Tween in casein solution (Thermo Fisher). Primary antibodies from rabbit for Cholecystokinin (CCK; ABcam, Cambridge, UK) and Cannabinoid Receptor 1 (Generously provided by Dr. Ken Mackie, Indiana University) were diluted 1:500 in blocking buffer and separately added to slides. Slides were washed three times with 0.1% Tween/PBS solution before being incubated with AlexaFluor 647 (Donkey anti-rabbit, Thermo Fisher). Tissue was washed again and mounted with Prolong Gold Antifade reagent with DAPI (Thermo Fisher) for nuclear counterstaining. Images were obtained at room temperature using an Axio Observer Z1 Inverted Microscope (Zeiss, Oberkochen, Germany) at 63× magnification with a CSU-X1 Confocal Scanner Unit (Yokogawa, Tokyo, Japan), and images were captured using a Prime 95B Scientific CMOS Camera (Photometrics, Huntington Beach, CA, USA). Micro-Manager open source software was used for image capture, and final images were optimized using ImageJ 1.51n (NIH, Bethesda, MD, USA).

Fluorescence-Activated Cell Sorting {#sec11}
-----------------------------------

### Isolation of Intestinal Epithelial Cells {#sec12}

Approximately, 4 cm of proximal small intestine was inverted and mechanically disrupted with frosted glass slides into ice-cold buffer containing 5% BSA, 0.6 mM dithiothreitol (DTT) and 1 mM EDTA in PBS to disrupt mucosal cell layer. Live cells were counted following trypan blue staining and 20 × 10^6^ cells were pelleted at 200 *g* for 5 min and resuspended in 1 ml of 3% BSA containing 1 mM EDTA in PBS. Cell suspension was filtered through 30-micron mesh and subsequently processed by fluorescence-activated cell sorting (FACS).

### FACS Sorting of eGFP (+) and eGFP (−) Cells {#sec13}

Isolated cells were sorted and analyzed on a MoFlo Astrios (Beckman Coulter, Brea, CA, USA). Debris was detected and excluded using forward and side scatter profiles generated with a 488 nm laser. eGFP positive (+) cells were detected by fluorescence intensity, using excitation and emission spectra of 488 and 513/26, respectively. A wild-type mouse from C57Bl/6 J background was used to establish autofluorescence, and gating for eGFP was used for final sorting (See [Figures 1D](#fig1){ref-type="fig"},[E](#fig1){ref-type="fig"}). Samples were sorted into fresh resuspension buffer prior to qPCR analysis of gene expression. Mice were fasted for 10 h prior to acquisition of cells.

![CB1Rs co-localize with CCK-containing cells in the upper small-intestinal epithelium. Immunohistochemical detection of eGFP \[CCK-eGFP (B, F, J)\] and CB~1~Rs \[CB~1~R-ab **(C, G, K)**\] reveals co-localization \[merge **(A, E, I)**\] in villi of intestinal epithelium. Arrows indicate separate enteroendocrine cells that contain immunoreactivity for CB~1~Rs that co-localize with CCK-eGFP cells. Representative images from three CCK-eGFP mice \[DAPI stain **(D,H,L)**\].](fphys-10-00704-g001){#fig1}

Enzyme Activity Assays {#sec14}
----------------------

### Tissue Preparation {#sec15}

Intestinal epithelium was collected as described above (2.3.1) and approximately 100 mg of frozen tissue was homogenized in 2 ml of ice-cold 50 mM Tris-HCl, 320 mM sucrose (pH 7.5) buffer. Homogenates were centrifuged at 800 *g* for 10 min at 4°C and supernatant was collected. Protein supernatants were sonicated twice for 10 s and then freeze-thawed in liquid nitrogen twice. Samples were spun again, and supernatant protein content was quantified using BCA assay and diluted to working concentration with Tris-HCl/sucrose buffer.

### DGL Activity Assay {#sec16}

Small-intestinal epithelial tissue homogenates (25 μg, room temperature) were incubated with the MGL inhibitor, JZL184 (0.3 μM), for 10 min in order to block MGL activity during the assay. Homogenates were then incubated in 0.2 ml solution of Tris-HCL with 0.2% Triton X-100 (pH 7.0) containing 20 nmol dinonadecadienoin (19:2 DAG) at 37°C for 30 min. Reactions were stopped by adding 1 ml of ice-cold MeOH containing 25 pmol \[^2^H~5~\]-2-AG as internal standard. Lipids were extracted and the product of the reaction, monononadecadienoin (19:2 monoacylglycerol), was analyzed *via* UPLC/MS/MS as described above for 19:2 monoacylglycerol (See "[LCMS Detection of 2-Arachidonoyl-*sn*-Glycerol and Other Monoacylglycerols](#sec8){ref-type="sec"}").

### MGL Activity Assay {#sec17}

Small-intestinal epithelial tissue (10 μg) was incubated with 0.4 ml solution of Tris-HCL with 0.1% BSA (pH 8.0) containing 50 nmol nonadecadienoin (19:2 monoacylglycerol; Nu-Chek Prep, Waterville, MN, USA; final volume 0.5 ml per reaction) at 37°C for 10 min. Reactions were stopped by adding 1 ml of MeOH containing 10 nmol heptadecanoic acid (17:1 FFA; Nu-Chek Prep) as internal standard. Lipids were extracted and the product of the reaction (19:2 free fatty acid) was analyzed *via* UPLC/MS/MS according to the following protocol. Data were acquired using equipment described above (See "[LCMS Detection of 2-Arachidonoyl-*sn*-Glycerol and Other Monoacylglycerols](#sec8){ref-type="sec"}") and eluted by a gradient of water and methanol (containing 0.25% acetic acid, 5 mM ammonium acetate) at a flow rate of 0.4 ml per min and gradient: 90% methanol 0.1 min, 90--100% methanol 0.1--2.0 min, 100% methanol 2.0--2.1 min, 100 to 90% methanol 2.1--2.2 min, and 90% methanol 2.2--2.5 min. Column was maintained at 40°C and samples were kept at 10°C in sample manager. MS detection was in negative ion mode with capillary voltage maintained at 3.00 kV. Cone voltages for nonadecadienoic acid (19:2 FFA) = 48v and heptadecanoic acid (17:1 FFA) = 64v. Lipids were quantified using a stable isotope dilution method of proton adducts of the molecular ions \[M--H\]^−^ in selected ion recording (SIR) mode. Tissue processing and LCMS analyses for experiments occurred independently of other experiments. Extracted ion chromatograms for SIR masses were used to quantify analytes: 19:2 FFA (*m/z* = 293.2) product of MGL enzyme assay and 17:1 FFA (*m/z* = 267.2) as internal standard.

### Gastric Emptying {#sec18}

To evaluate drug or endogenous endocannabinoid effects on gastric emptying, corn oil was spiked with 1.0 nmol 19:2 FFA and administered by oral gavage (500 μl), then quantities of 19:2 FFA remaining in the stomach were evaluated at the time of blood collection 30 min after gavage. The stomach was removed and immediately placed into methanol containing 17:1 FFA as internal standard. Lipids were extracted and 19:2 FFA was detected and quantified as above (See "[MGL Activity Assay](#sec17){ref-type="sec"}").

Gene Expression Analysis {#sec19}
------------------------

### RNA Isolation From Intestinal Epithelium {#sec20}

Total RNA was extracted from intestinal epithelium using RNeasy kit (Qiagen, Valencia, CA, USA) method, and first-strand complementary DNA was generated using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA). All surfaces for tissue collection and processing were sanitized using 70% ethanol and then treated with an RNAse inhibitor (RNAse out, G-Biosciences, St. Louis, MO, USA) to maintain integrity of isolated RNA. Reverse transcription of total RNA (1 μg epithelium) was performed as previously described ([@ref2]).

### RNA Isolation From Sorted Cells {#sec21}

Sorted cell suspensions were pelleted at 3,000 *g* for 10 min and resuspended in 0.5 ml of Qiazol (Qiagen, Valencia, CA) and subsequently processed using RNeasy kit to isolate total RNA. Reverse transcription was performed as described above using 50 ng total RNA.

### Quantitative Polymerase Chain Reaction Analysis {#sec22}

RT-qPCR was carried out using PrimePCR Sybr Green Assays (Biorad, Hercules, CA, USA) with the following primers for mouse genes: CB~1~R (Cnr1), CB~2~R (Cnr2), cholecystokinin (Cck), fatty-acid amide hydrolase (Faah), n-acyl phosphatidyl ethanolamine-specific phospholipase D (Napepld), diacylglycerol lipase alpha (Dagla) and beta (Daglb), monoacylglycerol lipase (Mgll), alpha-beta-hydrolyzing domain 6 (Abhd6) with Hprt and Actb as housekeeping genes for epithelium and sorted cells, respectively. Values are expressed as relative mRNA expression based on widely used methods \[i.e., delta-delta cq; see ([@ref60])\]. Reactions were run in triplicate for each animal.

Statistical Analysis {#sec23}
--------------------

Values are expressed as means ± SEM. Unpaired Student's two-tailed *t*-test was used to compare data for standard diet- and western diet-fed groups. Repeated measures two-way ANOVA was used for groups measured over time. Additionally, regular one-way and two-way ANOVA were used to determine differences in multiple groups with *post-hoc* Sidak's multiple comparisons tests or Newman-Keul's, as appropriate. Data were analyzed using GraphPad Prism6 software. Significance was determined as *p* \< 0.05. Statistical outliers were determined using Grubb's test in all datasets.

Results {#sec24}
=======

CB~1~Rs Are Expressed in CCK-Containing Cells in the Upper Small-Intestinal Epithelium {#sec25}
--------------------------------------------------------------------------------------

We reported that eCB levels are increased in the upper small-intestinal epithelium from mice maintained on a Western Diet (WD; high-fat and sucrose diet) for 60 days when compared to lean controls maintained on a low-fat and low-sugar diet, and inhibiting peripheral CB~1~Rs blocked overeating associated with consumption of WD (i.e., increased meal size, rate of food intake, and total caloric intake) ([@ref2]). To identify the molecular underpinnings of gut-brain eCB signaling important for feeding behavior and its dysregulation in DIO, we first evaluated whether CB~1~Rs are expressed in cells that produce and secrete the satiation peptide, CCK. CCK controls meal size and induces satiation by activating CCK~A~ receptors on the afferent vagus nerve ([@ref92], [@ref93]; [@ref88]; [@ref83]; [@ref80]; [@ref32]; [@ref85]). CB~1~R immunoreactivity was found in CCK-eGFP-positive cells from the upper small intestinal epithelium ([Figure 1](#fig1){ref-type="fig"}) in a mouse line that expresses eGFP selectively in CCK-expressing cells \[C57BL/6-Tg(Cck-EGFP)2Mirn/J\] ([@ref86]). Furthermore, immunoreactivity for CCK was co-localized with eGFP in the upper small-intestinal epithelium, which confirms expression of CCK in eGFP-containing cells from this mouse line ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). We, next isolated eGFP-positive and eGFP-negative cells from the upper small intestinal epithelium by fluorescence-activated cell sorting (FACS). Messenger RNA (mRNA) for CB~1~Rs (Cnr1) was enriched in CCK-eGFP-positive cells when compared to CCK-eGFP-negative cells ([Figure 2A](#fig2){ref-type="fig"}; eGFP-positive = 1.00 ± 0.24, eGFP-negative = 0.04 ± 0.04; *p* = 0.016; data from three mice). Moreover, mRNA for CCK was present in CCK-eGFP-positive cells isolated by FACS but was not present in CCK-eGFP-negative cells, which highlights the specificity of our FACS gating strategy for isolating CCK-eGFP cells and further confirms expression of CCK in these cells ([Figure 2B](#fig2){ref-type="fig"}). Our gating strategy was optimized for sorting of eGFP-positive and eGFP-negative events from cells isolated from the upper small-intestinal epithelium of CCK-eGFP mice (see [Figure 2C](#fig2){ref-type="fig"}). Cells from wild-type mice (see [Figure 2D](#fig2){ref-type="fig"}) show minimal fluorescence at less than 10% of levels found in CCK-eGFP cells: eGFP-positive cells comprise 0.63% of total cells analyzed from CCK-eGFP mice, and wild-type show 0.06%, likely due to autofluorescence (see [Supplementary Figure S2](#SM2){ref-type="supplementary-material"} for detailed FACS report). These results suggest that CCK-containing I-cells in the mouse upper small-intestinal epithelium are enriched in expression of CB~1~Rs.

![CB1R mRNA expression is enriched in CCK-containing cells in the upper small-intestinal epithelium. Fluorescence-activated cell sorting (FACS) of eGFP-CCK-positive (+) and eGFP-CCK-negative (−) cells from the upper small-intestinal epithelium reveals enhanced Cnr1 expression in eGFP-CCK-positive cells **(A)**. Expression of mRNA for CCK is found in eGFP-CCK-positive cells but not in eGFP-CCK-negative cells **(B)**. Gating strategy shown for sorting of eGFP-positive and eGFP-negative events, with eGFP-positive cells highlighted in green and demarked by thin line **(C)** and compared to upper small-intestinal epithelial cells from a wild-type (WT) mouse **(D)**. Data expressed as mean ± S.E.M. Analyzed using Student's *t*-test, two-tailed **(C)**; *n* = 3 per group; \**p* \< 0.05.](fphys-10-00704-g002){#fig2}

Peripheral CB~1~Rs Control Fat-Induced CCK Secretion {#sec26}
----------------------------------------------------

The arrival of fat and other macronutrients into the duodenum stimulates release of a variety of signaling molecules that include CCK, which is produced and secreted by enteroendocrine I-cells lining the upper small-intestinal epithelium ([@ref66]; [@ref79]; [@ref81]; [@ref19]; [@ref94]). We next tested the hypothesis that CB~1~Rs control nutrient-induced release of CCK from the upper small-intestinal epithelium. Oral gavage of corn oil (CO) in lean mice maintained on a standard rodent diet (SD; low-fat no-sucrose chow) increased plasma levels of bioactive CCK, CCK-8 (octapeptide), when compared to control mice that received oral gavage of saline \[[Figure 3A](#fig3){ref-type="fig"}; CO = 0.69 ± 0.11 ng per ml, saline control = 0.28 ± 0.02 ng per ml; *p* \< 0.05 CO versus saline control, *n* = 3--5). Peripheral administration of the general cannabinoid receptor agonist, WIN55,212-2 (WIN, 3 mg per kg), blocked CO-induced secretion of CCK-8 ([Figure 3A](#fig3){ref-type="fig"}; CO + WIN = 0.36 ± 0.04 ng per ml; *p* \< 0.05 CO + WIN versus CO alone, *n* = 5). Furthermore, the effect of WIN administration on CO-induced secretion of CCK-8 was reversed by co-treatment with the peripherally-restricted neutral CB~1~R-selective antagonist, AM6545 ([Figure 3A](#fig3){ref-type="fig"}; CO + WIN+AM6545 = 0.75 ± 0.14 ng per ml; *p* \< 0.05 CO + WIN versus CO + WIN+AM, *n* = 5; AM6545 10 mg per kg). These results suggest that exogenous activation of CB~1~Rs inhibits nutrient-induced CCK release from the upper gut.

![Exogenous or endogenous activation of peripheral CB1Rs inhibits fat-induced CCK release. Compared to control \[0.5 ml saline (Sal) by oral gavage and vehicle (Veh) by IP injection\], corn oil (CO; 0.5 ml by oral gavage) increased levels of CCK-8 in plasma of lean mice fed a low-fat no-sugar standard diet (SD), an effect blocked by the CB~1~R agonist, WIN 55,212-2 (WIN, IP 3 mg per kg 30 min before CO) **(A)**. The effects of WIN were inhibited by co-administration with the peripherally-restricted CB~1~R antagonist, AM6545 (AM; 10 mg per kg 30 min before CO). When compared to control SD mice (CO + SD), CO failed to elicit changes in levels of CCK-8 in plasma in mice fed western diet (WD) for 60 days, and inhibition of peripheral CB~1~Rs with AM6545 normalized levels of CCK-8 to those found in SD CO controls **(B)**. Data expressed as means ± S.E.M. Analyzed by one-way ANOVA with *post hoc* Newman-Keuls multiple comparison test. *n* = 3--5 per condition, \* *p* \< 0.05, \*\* *p* \< 0.01.](fphys-10-00704-g003){#fig3}

We next tested the hypothesis that elevated endogenous activity (e.g., increased 2-AG levels) at upper small-intestinal CB~1~Rs in mice maintained on Western Diet (WD; high-fat and sucrose diet) for 60 days inhibits CO-induced increases in circulating levels of CCK-8. We first confirmed that levels of 2-AG---among other monoacylglycerols---were increased in the upper small intestinal epithelium of WD mice, when compared to lean mice fed SD for 60 days (see [Table 1](#tab1){ref-type="table"}). Next, we tested the ability for oral gavage of CO to increase CCK-8 levels in plasma of WD mice. CO failed to affect levels of CCK-8 in WD mice when compared to mice fed a standard diet (SD) that is low in fat and absent of sucrose ([Figure 3B](#fig3){ref-type="fig"}; CO + WD = 0.33 ± 0.04 ng per ml, CO + SD = 0.8 ± 0.03 ng per ml; *p* \< 0.01, *n* = 5). Furthermore, AM6545 treatment in WD mice that received oral gavage of CO increased levels of CCK-8 to those comparable to SD mice under the same conditions ([Figure 3B](#fig3){ref-type="fig"}; CO + WD + AM = 0.7 ± 0.1 ng per ml; *p* \< 0.01 CO + WD versus CO + WD + AM, *n* = 6). Collectively, these results suggest that exogenous or endogenous activation of CB~1~Rs in the upper small intestinal epithelium inhibits nutrient-induced CCK secretion.

###### 

Impact of diet on monoacylglycerols in mouse small-intestinal epithelium.

  -----------------------------------------------------------------------------------------------------
  MAG   20:4 (2-AG)\    18:1\           18:2\           16:0\           22:6\           Total\
        (nmol g^−1^)    (nmol g^−1^)    (nmol g^−1^)    (nmol g^−1^)    (nmol g^−1^)    (nmol g^−1^)
  ----- --------------- --------------- --------------- --------------- --------------- ---------------
  SD    80.23 ± 8.542   49.57 ± 9.804   217.7 ± 52.09   33.99 ± 4.125   9.413 ± 1.996   390.9 ± 72.24

  WD    132.5 ± 22.20   109.0 ± 22.03   415.3 ± 83.26   150.1 ± 21.53   22.63 ± 3.703   829.4 ± 144.2

  *p*   **0.0353**      **0.0206**      0.0554          **\<0.0001**    **0.0049**      **0.0122**
  -----------------------------------------------------------------------------------------------------

MAG, Monoacylglycerol represented as fatty acid chain; SD, Standard diet *n* = 10; WD, Western diet *n* = 9. Mean values are shown as ± S.E.M. Bold values are significantly different determined by two-tailed unpaired *t*-test.

All levels of CCK-8 in these experiments fell within the range of the standard curve for CCK-8 quantitation by a sensitive and selective CCK-8 ELISA, which shows no cross-reactivity for gastrin (see [Supplementary Figure S3](#SM3){ref-type="supplementary-material"}), another gut-derived peptide that shares some common molecular features with CCK-8 ([@ref105]; [@ref35]; [@ref107]; [@ref90]). Furthermore, the range of CCK-8 levels in our studies (from 0.27 ± 0.02 to 0.8 ± 0.03 ng per ml or 0.23 ± 0.02 to 0.7 ± 0.03 nM) aligns with reported *K~i~* and EC~50~ values of sulfated CCK-8 in several binding and *in vitro* bioassays (e.g., amylase release from pancreatic acini and ileum contractions in guinea pig) ([@ref13]).

CB~1~R activation is reported to decrease gastric emptying, an effect also found in mice fed a high-fat diet for 14 weeks ([@ref74]; [@ref24]). To identify if altered gastric emptying occurs under our conditions and may contribute in part to inhibited corn oil-induced CCK release, we developed a novel UPLC/MS/MS-based method to evaluate if CB~1~R activation with WIN 55,212-2 or exposure to WD for 60 days impacts gastric emptying following oral gavage of corn oil in SD and WD mice, respectively. Thirty minutes after administration of drugs, we administered by oral gavage corn oil (500 μl) that contained 19:2 free-fatty acid (1 nmol) as a tracer and measured by UPLC/MS/MS the remaining quantities of 19:2 free-fatty acid in the stomach 30 min after gavage. WIN 55,212-2 (3 mg per kg) alone or in combination with AM6545 (10 mg per kg) had no effect on gastric emptying of corn oil in SD mice (see [Supplementary Figure S4A](#SM4){ref-type="supplementary-material"}). Similarly, WD mice displayed no changes in gastric emptying of corn oil when compared to SD mice (see [Supplementary Figure S4B](#SM4){ref-type="supplementary-material"}). These data suggest that exogenous activation (WIN in SD mice) or endogenous activation (elevated small intestinal epithelial eCB levels in WD mice) of CB~1~Rs does not affect gastric emptying of corn oil under our conditions, and does not likely impact CCK release by a mechanism that includes alterations in gastric emptying in mice.

CB~1~Rs in pancreatic beta cells control insulin release and glucose homeostasis ([@ref49]; [@ref23]; [@ref5]; [@ref71]; [@ref55]; [@ref39]). Thus, we tested if drug treatment impacted glucose levels in response to corn oil gavage in SD mice, which in turn, could affect gastric emptying, motility, or enteroendocrine hormones from small intestinal enteroendocrine cells. Glucose levels in blood were collected from tail vein and monitored *via* hand-held glucose monitor at (1) time of drug administration, (2) 30 min later just prior to corn oil gavage, and (3) 30 min later at time of kill (See [Supplementary Figure S5](#SM5){ref-type="supplementary-material"}). Drug treatment had no significant impact on blood glucose levels at any time point prior to or after gavage of corn oil (See [Supplementary Figure S5](#SM5){ref-type="supplementary-material"}). These data suggest that, under our conditions, activating CB~1~Rs does not impact blood glucose levels following oral gavage of corn oil in mice.

Activity of Enzymes Responsible for Metabolism of 2-AG and Other Monoacylglycerols Is Dysregulated in the Upper Small-Intestinal Epithelium in Mice Chronically Fed WD {#sec27}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

We next aimed to identify the mechanism(s) of increased 2-AG and related monoacylglycerol levels (see [Table 1](#tab1){ref-type="table"}) in WD mice by analyzing activity of their biosynthetic \[diacylglycerol lipase (DGL)\] and degradative enzymes \[monoacylglycerol lipase (MGL)\] using our lab's UPLC/MS/MS-based functional enzyme assay methods (see [Supplementary Figure S6](#SM6){ref-type="supplementary-material"} for validation of enzyme assays). When compared to SD mice, WD mice displayed an increase in activity of DGL ([Figure 4A](#fig4){ref-type="fig"}; SD = 0.12 ± 0.02, WD = 0.22 ± 0.03 nmol per mg protein per min; *p* = 0.016, reactions from six mice per diet group), and MGL ([Figure 4B](#fig4){ref-type="fig"}; SD = 36.32 ± 3.82, WD = 51.60 ± 4.95 nmol per mg protein per min; *p* = 0.035, reactions from six mice per diet group) in isolated tissue from the upper small intestinal epithelium. Congruent with data in [Table 1](#tab1){ref-type="table"} and ([@ref2]), these effects were met with increased levels of 2-AG in upper small intestinal epithelium of separate mice ([Figure 4C](#fig4){ref-type="fig"}; SD = 45.71 ± 6.93, WD = 92.57 ± 16.41 nmol per g; *p* = 0.014, *n* = 9--10 per diet group). See [Figure 4D](#fig4){ref-type="fig"} for diagram of the 2-AG metabolic pathways. Together, these results suggest that monoacylglycerol metabolic pathways are dysregulated after chronic exposure to WD, which leads to a net increase in monoacylglycerols, including 2-AG, in the upper small-intestinal epithelium.

![2-AG biosynthesis and degradation are upregulated in small intestine during obesity. Hydrolytic activity of DGL **(A)** and MGL **(B)** are increased in mice maintained on western diet (WD) when compared to controls fed a standard diet (SD). Levels of the endocannabinoid, 2-AG, are increased in jejunum mucosa of WD mice, when compared to SD mice **(C)**. 2-AG is formed by the hydrolysis of its 1,stearoyl,2-arachidonoyl-*sn*-glycerol precursor by DGL and is subsequently degraded by MGL into arachidonic acid and glycerol **(D)**. Data expressed as mean ± S.E.M. Analyzed using Student's two-tailed *t*-test. *n* = 6 per condition, \**p* \< 0.05.](fphys-10-00704-g004){#fig4}

Expression of Select eCB System Components in the Upper Small-Intestinal Epithelium Is Dysregulated in Mice Chronically Fed WD and Partially Conserved in CCK-Positive Cells {#sec28}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Relative expression of mRNA for intestinal CCK, CB~1~Rs, and CB~2~Rs (Cnr2) was unchanged in whole upper small intestinal epithelial scrapings from mice fed WD versus SD mice ([Figure 5A](#fig5){ref-type="fig"}; CCK, SD = 1.00 ± 0.76, WD = 0.56 ± 0.45, *p* = 0.64; Cnr1, SD = 1.00 ± 0.36, WD = 0.79 ± 0.31, *p* = 0.67; Cnr2, SD = 1.00 ± 0.31, WD = 0.83 ± 0.19, *p* = 0.65; data from four mice per diet group). Expression of mRNA for the alpha isoform of DGL (Dagla) was also unaffected by diet ([Figure 5A](#fig5){ref-type="fig"}; SD = 1.00 ± 0.25, WD = 0.90 ± 0.29, *p* = 0.80); however, expression of mRNA for the beta isoform of DGL (Daglb) was reduced in WD versus SD mice ([Figure 5A](#fig5){ref-type="fig"}; SD = 1.00 ± 0.15, WD = 0.35 ± 0.03, *p* = 0.005), while mRNA for MGL (Mgll) and the serine hydrolase alpha/beta hydrolase domain 6 (Abhd6) were increased in small intestinal epithelium under the same conditions ([Figure 5A](#fig5){ref-type="fig"}; Mgll, SD = 1.00 ± 0.17, WD = 2.71 ± 0.46, *p* = 0.013; Abhd6, SD = 1.00 ± 0.16, WD = 1.54 ± 0.05, *p* = 0.02). No changes were found for the fatty acid ethanolamide biosynthetic enzyme, NAPE-PLD, or the fatty acid ethanolamide degradative enzyme, FAAH ([Figure 5A](#fig5){ref-type="fig"}; NAPE-PLD, SD = 1.00 ± 0.18, WD = 0.89 ± 0.08, *p* = 0.6; FAAH, SD = 1.00 ± 0.17, WD = 1.00 ± 0.07, *p* = 0.99). Furthermore, the upper small-intestinal epithelium is enriched in expression of mRNA for Daglb when compared to Dagla ([Figure 5A](#fig5){ref-type="fig"} inset; Dagla = 1.00 ± 0.19, Daglb = 29.73 ± 4.3; *p* = 0.001; data from four mice fed SD).

![Expression of select components of the eCB system is dysregulated in the upper small intestine of DIO mice and partially conserved in CCK-eGFP+ cells. Expression of mRNA for cholecystokinin (Cck), cannabinoid receptor subtype 1 (Cnr1) and 2 (Cnr2), and other components of the eCB system in upper small-intestinal mucosal scrapings are not impacted by western diet (WD) exposure when compared to controls fed a standard diet (SD) **(A)**. Expression of diacylglycerol lipase beta (Daglb) is decreased, and expression of the degradative enzymes monoacylglycerol lipase (Mgll) and alpha-beta hydrolyzing domain 6 (Abhd6) are increased in WD mice. Expression of mRNA for CCK or components of the eCB system were not significantly affected by diet in eGFP (+) sorted cells **(B)**. Expression of mRNA for diacylglycerol lipase alpha (Dagla), Mgll, and N-acyl phosphatidylethanolamine specific phospholipase D (Napepld) was not detected (ND) **(B)**. Data expressed as mean ± S.E.M. Analyzed using Student's two-tailed *t*-test. *n* = 3 per group in triplicate and \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 **(A)**; *n* = 3 per group in triplicate, *p* \> 0.05 **(B)**.](fphys-10-00704-g005){#fig5}

It is important to note, in contrast to our previous report that included analysis of eCB system expression in the upper small intestinal epithelium of mice maintained on WD and SD \[Lab Diet 5001 used in ([@ref2])\], in this study we used a soy protein-free Teklad 2020x as a control SD in order to eliminate any potential effects of phytoestrogen-containing soy protein on eCB metabolism or behavior \[see ([@ref65]; [@ref101], [@ref100]; [@ref73])\]. We found two differences in results when comparing use of the two control diets versus WD. We reported no changes in expression of mRNA for the beta isoform of DGL and increases in expression of mRNA for FAAH in WD mice when compared to control SD mice ([@ref2]); however, in this study, we found decreased expression of mRNA for the beta isoform of DGL and no changes in expression of mRNA for FAAH in WD mice when compared to SD mice. These differences highlight possible effects of diets that utilize soy protein on expression of eCB metabolic enzymes and eCB metabolic function. A direct comparison of the impact of specific control diets on expression of eCB system components, however, remains to be evaluated.

CCK-eGFP-positive cells isolated from mice fed SD or WD mice displayed no differences between diet condition in expression of mRNA for CCK and components of the eCB system that include Cnr1, Cnr2, Daglb, Abhd6, and FAAH ([Figure 5B](#fig5){ref-type="fig"}; *p* \> 0.05 not significant, data from three mice per diet group). Dagla, Mgll, and Napepld mRNA were below detectable levels, which suggest a lack of expression of these eCB system components in CCK-containing cells.

Collectively, these results identify select eCB system gene transcripts in CCK-containing cells, and changes in expression of biosynthetic and degradative enzyme gene transcripts in whole epithelium of WD mice that do not fully correspond to changes in activity of their proteins, including DGL and MGL (see [Figure 4](#fig4){ref-type="fig"}). The latter suggests possible post-transcriptional and/or post-translational changes in expression of these enzymes in the upper small-intestinal epithelium in WD mice when compared to lean SD mice, although this hypothesis remains to be directly tested. Furthermore, a lack of expression of the fatty acid ethanolamide (FAE) biosynthetic enzyme, NAPE-PLD, in CCK-containing cells suggests that FAEs including anandamide---which is also found in small intestinal epithelium of rodents ([@ref48]; [@ref27], [@ref29], [@ref28]; [@ref2]; [@ref72])---is generated in neighboring cells and therefore may act in a paracrine manner with I-cells that contain CB~1~Rs. In contrast, expression of mRNA for the beta isoform of the monoacylglycerol biosynthetic enzyme, DGL, is abundantly expressed in CCK-containing cells, which suggests that 2-AG may signal at CB~1~Rs in an autocrine manner at these cells. Expression of the primary 2-AG degradative enzyme, MGL, is absent in CCK-containing I-cells, which suggests that 2-AG is degraded at adjacent cells and therefore may additionally signal CB~1~Rs on adjacent cells in a paracrine manner. A comprehensive analysis of eCB system architecture and its cell-specific expression in the upper small-intestinal epithelium of mice remains for future studies.

Western Diet Exposure for 60 Days Is Associated With Obesity and Hyperphagia in Male Mice {#sec29}
-----------------------------------------------------------------------------------------

Consistent with our previous studies ([@ref2]), exposure to WD for 60 days, when compared to lean mice fed SD for 60 days, was associated with (1) a rapid and sustained increase in body mass when compared to control mice fed SD for 60 days, (2) increased 24 h meal size, (3) rate of food intake, and (4) total 24 h caloric intake (see [Supplementary Figure S7](#SM7){ref-type="supplementary-material"} and [Table 2](#tab2){ref-type="table"} for details and data). No significant changes were found for other feeding behaviors including (1) first meal size, (2) meal frequency, (3) meal duration, and (4) post-meal interval. As discussed above in "[Expression of Select eCB System Components in the Upper Small Intestinal Epithelium is Dysregulated in Mice Chronically Fed WD and Partially Conserved in CCK-Positive Cells](#sec28){ref-type="sec"}," in contrast to our previous study ([@ref2]), in this study we used a soy-protein-free lab chow. Irrespective of control diet, however, WD intake was consistently associated with increased 2-AG levels ([Table 1](#tab1){ref-type="table"}) and hyperphagia across relevant parameters in both studies ([Table 2](#tab2){ref-type="table"}, [Figure 6](#fig6){ref-type="fig"}; [@ref2]). Together, these data suggest that exposure to a WD rapidly induces body weight gain that is met with increased meal size, rate of intake, and daily caloric intake, when compared to lean controls.

###### 

Consumption of WD is associated with hyperphagia.

        Δ Body mass (g)   Meal size (kcal)   Intake rate (kcal min^−1^)   24 h Intake (kcal)   First meal (kcal)   Frequency (meals day^−1^)   Duration (Min)   PMI (Min)
  ----- ----------------- ------------------ ---------------------------- -------------------- ------------------- --------------------------- ---------------- --------------
  SD    8.90 ± 0.31       0.69 ± 0.04        0.33 ± 0.02                  8.10 ± 0.61          0.72 ± 0.11         11.67 ± 0.45                8.61 ± 1.16      114.7 ± 8.4
  WD    18.14 ± 0.46      1.29 ± 0.10        0.71 ± 0.08                  13.28 ± 0.81         1.99 ± 0.66         9.83 ± 1.42                 6.85 ± 0.98      129.3 ± 14.3
  *p*   **\<0.0001**      **\<0.0001**       **\<0.0001**                 **\<0.0001**         0.07                0.23                        0.26             0.31

*PMI, Post meal interval. Mean values are shown as ± S.E.M. *n* = 10. Bold values are significantly different determined by two-tailed unpaired *t*-test*.

![Peripheral eCB signaling drives hyperphagia in mice maintained on a WD *via* a CCK-dependent mechanism. Caloric intake **(A)**, meal size **(B)**, and rate of intake **(C)** of a western diet (closed bars) are significantly reduced during a 12 h test following inhibition of peripheral CB~1~Rs with AM6545 (AM, 10 mg per kg), an effect absent in low-fat chow fed mice (open bars) and that is blocked by co-administration with the CCK~A~ receptor antagonist, devazepide (Dev; 0.1 mg per kg). Diet and drug had no effect on meal frequency **(D)**, meal duration **(E)**, post meal interval **(F)**, or first meal size **(G)**. All data represented as means ± SEM. Analyzed using regular 2-Way ANOVA with *post hoc* Newman-Keuls multiple comparison's test. *n* = 11--12 per condition, \**p* \< 0.05, \*\**p* \< 0.01.](fphys-10-00704-g006){#fig6}

Pharmacological Inhibition of CCK~A~ Receptors Blocks the Anorexic Effect of AM6545 in Mice Chronically Fed a WD {#sec30}
----------------------------------------------------------------------------------------------------------------

We next tested the hypothesis that peripheral CB~1~Rs control feeding behavior by a mechanism that includes control of CCK-mediated satiation signaling. When compared to vehicle treatment in mice fed WD for 60 days, AM6545 treatment (10 mg per kg) in WD mice reduced meal size ([Figure 6A](#fig6){ref-type="fig"}; vehicle = 1.47 ± 0.15 kcal, AM6545 = 1.13 ± 0.67 kcal; *p* \< 0.05, *n* = 12), rate of intake ([Figure 6B](#fig6){ref-type="fig"}; vehicle = 0.76 ± 0.12 kcal per min, AM6545 = 0.46 ± 0.05 kcal per min; *p \<* 0.01), and total caloric intake ([Figure 6C](#fig6){ref-type="fig"}; vehicle = 9.11 ± 0.67 kcal per min, AM6545 = 6.62 ± 0.69 kcal per min; *p* \< 0.01) during a 12 h test, which is consistent with our previous findings ([@ref2]). Furthermore, AM6545 treatment in mice fed SD for 60 days did not affect meal size ([Figure 6A](#fig6){ref-type="fig"}; vehicle = 0.74 ± 0.05 kcal, AM6545 = 0.71 ± 0.04 kcal; *p* \> 0.05, *n* = 12), rate of intake ([Figure 6B](#fig6){ref-type="fig"}; vehicle = 0.30 ± 0.03 kcal per min, AM6545 = 0.32 ± 0.03 kcal per min; *p* \> 0.05), and total caloric intake ([Figure 6C](#fig6){ref-type="fig"}; vehicle = 5.51 ± 0.42 kcal per min, AM6545 = 5.45 ± 0.28 kcal per min; *p* \> 0.05) during a 12 h test. Importantly, co-administration of a low dose of the CCK~A~ receptor antagonist, devazepide (Dev; 0.1 mg per kg), in WD mice blocked the effects of AM6545 on reducing meal size ([Figure 6A](#fig6){ref-type="fig"}; vehicle = 1.47 ± 0.15 kcal, AM6545 + devazepide = 1.49 ± 0.16 kcal; *p* \> 0.05), rate of intake ([Figure 6B](#fig6){ref-type="fig"}; vehicle = 0.76 ± 0.12 kcal per min, AM6545 + devazepide = 0.62 ± 0.06 kcal per min; *p* \> 0.05), and total caloric intake ([Figure 6C](#fig6){ref-type="fig"}; vehicle = 9.11 ± 0.67 kcal per min, AM6545 + devazepide = 8.98 ± 0.67 kcal per min; *p* \> 0.05). Administration of devazepide alone affected only total 12-h caloric intake in SD mice ([Figure 6C](#fig6){ref-type="fig"}; vehicle = 5.51 ± 0.42 kcal per min, devazepide = 7.61 ± 0.33 kcal per min; *p \<* 0.05). Neither AM6545 nor devazepide affected other meal parameters including meal frequency ([Figure 6D](#fig6){ref-type="fig"}), meal duration, ([Figure 6E](#fig6){ref-type="fig"}), post-meal interval ([Figure 6F](#fig6){ref-type="fig"}), or first-meal size ([Figure 6G](#fig6){ref-type="fig"}) in SD or WD mice. These data suggest that the acute anorexic effects of AM6545 in WD mice are dependent on a mechanism that includes activation of CCK~A~ receptors and inhibition of gut-brain satiation signaling.

Discussion {#sec31}
==========

The molecular underpinnings of gut-brain signaling and their dysregulation in DIO are poorly defined. Our studies suggest that eCB activity at CB~1~Rs in the upper small intestinal epithelium is upregulated in mice chronically fed a WD, which in turn, promotes overeating by a mechanism that includes inhibiting nutrient-induced gut-brain satiation signaling (see [Figure 7](#fig7){ref-type="fig"} for model). Six primary findings support this conclusion: (1) CB~1~Rs are enriched in CCK-containing cells in the mouse upper small intestinal epithelium; (2) oral gavage of corn oil increased circulating levels of CCK-8 in lean mice, and pharmacological activation of CB~1~Rs blocked this effect, which was reversed by inhibition of peripheral CB~1~Rs with a peripherally-restricted CB~1~R neutral antagonist; (3) levels of 2-AG and other monoacylglycerols were increased in the upper-small intestinal epithelium of WD mice when compared to lean mice, and this effect was associated with dysregulated monoacylglycerol metabolism; (4) oral gavage of corn oil failed to affect circulating levels of CCK-8 in WD mice, and inhibition of peripheral CB~1~Rs in WD mice restored the ability for corn oil to increase CCK levels; (5) pharmacological inhibition of peripheral CB~1~Rs in WD mice blocked overeating associated with increased meal size, rate of feeding, and total caloric intake; and (6) the hypophagic effects of peripheral CB~1~R antagonism in WD mice were reversed by pretreatment with a low-dose CCK~A~ receptor antagonist. Collectively, our studies identify a previously unknown role for the eCB system at the interface of nutrient-sensing and gut-brain satiation signaling that becomes dysregulated in DIO and promotes overeating by delaying satiation.

![Model of CB1R control of nutrient-induced CCK release. Our studies suggest that cannabinoid CB~1~Rs in the upper small-intestinal epithelium control nutrient-induced satiation signaling, and their signaling is increased in diet-induced obesity, which drives overeating by delaying satiation. The upper small-intestinal epithelium contains enteroendocrine I-cells, which are a subpopulation of enterocytes that secrete cholecystokinin (CCK) when nutrients -- including dietary fats -- enter the lumen ([@ref82]; [@ref99]; [@ref106]; [@ref57]; [@ref7]). Dietary fats (e.g., corn oil), in the form of triacylglycerols, are hydrolyzed in the lumen into mostly monoacylglycerols and free-fatty acids (FFAs) that are sensed by free-fatty acid receptors (FFARs) located on enteroendocrine cells in the small-intestinal epithelium. Activation of FFARs stimulates secretion of CCK by a mechanism that requires calcium (Ca^2+^) influx and/or intracellular (i.e., endoplasmic reticulum, ER) mobilization ([@ref67]; [@ref42]; [@ref99]). CCK activates CCK~A~ receptors located on adjacent afferent sensory vagal fibers, which in turn, communicate with the brain and control meal size and satiation ([@ref92], [@ref93]; [@ref88]; [@ref53]). Consumption of a Western diet (WD) is associated with increased levels of the endocannabinoids (eCBs) and their activity at CB~1~Rs in the upper small-intestinal epithelium, which we propose inhibits CCK release and satiation signaling. The molecular mechanism(s) mediating CB~1~R control of CCK release is unknown, but may include inhibition of Ca^2+^-mediated CCK release. A future test of this hypothesis is warranted.](fphys-10-00704-g007){#fig7}

Our studies suggest that the eCB system in the small intestinal epithelium controls feeding behavior by a mechanism that includes inhibiting nutrient-induced release of the gut-derived satiation peptide, CCK, which in turn increases meal size and caloric intake. CCK is secreted from enteroendocrine I-cells in the upper small intestinal epithelium after nutrients arrive in the lumen ([@ref66]; [@ref81]; [@ref94]; [@ref53]) and controls meal size and induces satiation by activating CCK~A~ receptors on afferent vagal fibers ([@ref92], [@ref93]; [@ref88]; [@ref80]; [@ref53]; [@ref87]) and possibly the brain ([@ref83]; [@ref85]). Indeed, polymorphisms in CCK~A~ receptor genes in humans are associated with increased meal size and food intake, and obesity ([@ref68]; [@ref63]; [@ref21]). Furthermore, CCK in a stabilized form resistant to degradation in the GI tract is effective at reducing food intake and body weight in DIO rodents ([@ref76]; [@ref44], [@ref46]), and activating CCK~A~ receptors enhances the anti-obesity properties of GLP-1 agonists, amylin, and leptin ([@ref103], [@ref102]; [@ref45], [@ref47]).

Gene transcripts and immunoreactivity for CB~1~Rs were found in CCK-containing I-cells in the upper small-intestinal epithelium of mice (see [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}; [@ref96]). Furthermore, the hypophagic effects of AM6545 were blocked by co-administration of the CCK~A~ receptor antagonist, devazepide. These results suggest that when eCB activity is elevated at local CB~1~Rs in the upper small-intestinal epithelium in DIO, increased CB~1~R activation may inhibit nutrient-induced release of satiation peptides from small-intestinal enteroendocrine cells and lead to increased meal size and caloric intake. In support of this hypothesis, oral gavage of corn oil---which potently increases circulating levels of bioactive CCK-8 in lean mice that have low levels of small-intestinal eCB levels---failed to affect circulating levels of CCK-8 in mice chronically fed WD that have elevated eCB levels in the small-intestinal epithelium. Moreover, inhibiting elevated eCB signaling at peripheral CB~1~Rs with AM6545 in WD mice---at a dose that blocked overeating---restored the ability for corn oil to increase circulating levels of CCK-8.

The mechanisms of CB~1~R control of nutrient-induced release of CCK from enteroendocrine I-cells in the upper small-intestinal epithelium are unknown. Nonetheless, a primary mechanism by which CB~1~Rs block neurotransmitter release is by inhibiting calcium influx or mobilization ([@ref43]; [@ref75]), and nutrient-induced CCK release is calcium-dependent ([@ref67]; [@ref37]; [@ref42]; [@ref58]; [@ref70]). Thus, CB~1~R activity may inhibit release of gut peptides by a mechanism that includes inhibiting calcium influx or mobilization; however, a direct test of this hypothesis remains to be performed (see [Figure 7](#fig7){ref-type="fig"} for proposed mechanism).

It is controversial if obesity impacts CCK secretion \[see for review, ([@ref94])\]. In line with our present findings in mice, several studies suggest that CCK secretion is reduced in obese humans: fasting CCK levels were lower than non-obese ([@ref3]) and a trend toward lower CCK release after intra-duodenal infusions of oleic acid in overweight or obese subjects ([@ref95]). Fat-induced CCK secretion and satiation induced by CCK administration were also reduced in rats fed a high-fat diet ([@ref33]). Other studies, however, reported no differences in CCK levels between obese or lean humans following a meal ([@ref7]), and increases in CCK after a high-fat meal ([@ref36]). Furthermore, several preclinical studies in rodents suggest that sensitivity of vagal afferent neurons to the satiating effects of CCK may be decreased in DIO ([@ref18]; [@ref20]; [@ref33]; [@ref22]). This phenomenon may be due, in part, to changes in membrane properties of neurons in the nodose ganglion. The satiating actions of a physiological dose of CCK, however, were equally effective in suppressing food intake in obese and lean human subjects ([@ref56]). Moreover, a variety of studies conducted over the past several decades show that CCK-induced satiation is mediated by the vagus nerve ([@ref92], [@ref93]; [@ref88]; [@ref80]; [@ref32]; [@ref53]; [@ref87]); however, selected studies show that gut-derived CCK may additionally interact with CCK-A receptors in the brain ([@ref83]; [@ref85]). We used the brain-penetrant CCK-A receptor antagonist, devazepide, in our studies; therefore, we cannot rule out the possibility that CCK-A receptors in the brain participate in the appetite-suppressing effects of CCK release following inhibition of peripheral CB~1~Rs. Thus, given discrepancies in the literature regarding the underlying mechanisms of gut-brain signaling and its dysregulation in DIO, it is critical to examine the impact of diet and obesity on gut-brain satiation signaling using reliable and reproducible model systems.

It is plausible that CB~1~R control of nutrient-induced CCK release is one of several mechanisms by which peripheral CB~1~Rs impact gut-brain signaling pathways ([@ref8], [@ref9]; [@ref15]). For example, administration of ghrelin -- which is produced in the stomach and upper small intestinal epithelium and increases feeding \[see for review, ([@ref94]; [@ref52])\] -- blocked downregulation of CB~1~Rs in the nodose ganglion after, both, re-feeding and CCK administration in fasted rats ([@ref9]). Moreover, pharmacological inhibition of CB~1~Rs blocked fasting-induced ghrelin production in rats ([@ref12]; [@ref1]; [@ref89]), which suggests that CB~1~Rs in the upper GI tract may control ghrelin signaling. Furthermore, Kunos and colleagues reported that a peripherally-restricted CB~1~R inverse agonist improved a host of metabolic parameters as well as reducing food intake in DIO mice by a mechanism that may include reversing hyperleptinemia and leptin resistance associated with DIO ([@ref97]) and restoring anorexic melanocortin signaling in the arcuate nucleus of the hypothalamus ([@ref98]). Bellocchio and colleagues reported that the hypophagic effects of CB~1~R inhibition with the CB~1~R inverse agonist, rimonabant, is blocked by pharmacological inhibition of peripheral beta-adrenergic neurotransmission ([@ref4]), which suggests that CB~1~Rs may additionally control feeding behavior *via* interactions with the peripheral sympathetic nervous system. This study also showed that intact afferent vagal signaling was required for the hypophagic effects of rimonabant, and CB~1~Rs in the brain were not required for its pharmacological actions. Nonetheless, circulating levels of the eCBs increase in human and rodent models of obesity ([@ref34]; [@ref6]; [@ref17]; [@ref25]; [@ref64]; [@ref2]; [@ref41]; [@ref91]; [@ref59]), which may directly interact with CB~1~Rs in the brain and control feeding behavior and energy homeostasis. A comprehensive analysis of this possibility remains to be performed. In addition to I-cells in the small intestinal epithelium (see [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}; [@ref96]), CB~1~Rs are also expressed in K-cells that produce and secrete glucose-dependent insulinotropic peptide \[GIP ([@ref69]; [@ref84])\]. Pharmacological activation of CB~1~Rs inhibits GIP release in rodents, which suggests that local CB~1~Rs may impact glucose homeostasis *via* a mechanism that includes controlling nutrient-induced incretin release. Lastly, enteroendocrine cells in the intestinal lining form functional synapses with afferent vagal fibers ([@ref53]). Termed "neuropods" by Bohorquez and colleagues, these cells sense nutrients and release glutamate and CCK in a coordinated manner that interact with corresponding receptors on local afferent vagal fibers, which in turn, communicate with the brain. Our data suggest that CB~1~Rs may be at the interface of this signaling. It is unknown, however, if CB~1~Rs control glutamate signaling at these synapses in the small intestine as they do in the brain ([@ref50]). Collectively, these studies---in combination with the present report---describe key roles for peripheral CB~1~Rs in feeding behavior and energy homeostasis.

In summary, our results provide evidence of a previously unknown mechanism of CB~1~R-mediated inhibition of gut-brain satiation signaling in DIO that promotes overeating. Pharmacological manipulation of these pathways in the periphery may provide a therapeutic advantage for the treatment of obesity and related metabolic disorders when compared to anti-obesity drugs that interact with the brain and display psychiatric side-effects ([@ref14]; [@ref54]). Despite the peripherally-restricted properties of these CB~1~R antagonists, however, their impact on cognition and brain function by altering gut microbe activity is unknown and remains to be reported.
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2-AG

:   2-Arachidonoyl-*sn*-glycerol

Abhd6

:   alpha-beta-hydrolyzing domain 6
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:   Anandamide
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CB~1~R

:   Cannabinoid receptor subtype 1

CB~2~R

:   Cannabinoid receptor subtype 2

CCK

:   Cholecystokinin

CO

:   Corn oil

DAG

:   Diacylglycerol
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:   Devazepide

DGL

:   Diacylglycerol lipase

DIO

:   Diet-induced obesity

eCB

:   Endocannabinoid

eGFP

:   Enhanced green fluorescent protein

FAAH

:   Fatty acid amide hydrolase

FACS

:   Fluorescence activated cell sorting

FAE

:   Fatty acid ethanolamide

MAG

:   Monoacylglycerol

MGL

:   Monoacylglycerol lipase

NAPE-PLD

:   N-acyl phosphatidylethanolamine-specific phospholipase D

SD

:   Standard diet

WD

:   Western diet

WIN

:   WIN 55,212-2.
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